Abstract
From June 1990 to October 1994, 111 advanced ovarian cancer patients with minimal (less than 2 cm) residual disease after platinum-based front-line chemotherapy and second-look laparotomy entered a cooperative randomized study aimed at evaluating the effectiveness and the toxicity of the addition of interferon-alpha2 to carboplatin, both intraperitoneally (ip) administered. Patients were randomized to receive either 3 courses of ip Carboplatin 400 mg/m2 Day 1 q 28 days (54 pts) (CBDCA) or ip interferon-alpha 25 x 10(6) U Day 1 + ip carboplatin 400 mg/m2 Day 2 q 28 days (57 pts) (CBDCA + IFN). Patients treated with interferon experienced more severe (WHO grade 3-4) leukopenia (28% vs 17.1%) and anemia (14% vs 4.2%). Fever (P = 0.000) and flu-like syndrome (P = 0.02) were significantly more frequent in the combination arm. No difference in gastroenteric, neurologic, or renal toxicity was observed. At a median follow-up time of 13 months (range 1-72) 71 patients showed a disease progression (31 CBDCA, 40 CBDCA + IFN) and 44 patients died (21 CBDCA, 23 CBDCA + IFN). Median progression-free survival was 11 months in the CBDCA group and 10 months in the CBDCA + IFN arm. Median survival was 22 and 29 months in CBDCA and CBDCA + IFN ar...Continue Reading
References
Jan 1, 1992·Oncology·M O NicolettoS Monfardini
Oct 1, 1992·Cancer·J MenczerH Brenner
Feb 1, 1992·American Journal of Clinical Oncology·A de GramontJ Cady
Jan 1, 1992·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·P H WillemseN H Mulder
Apr 1, 1992·Gynecologic Oncology·M MarkmanH D Homesley
Mar 1, 1990·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·P H WillemseD T Sleijfer
Sep 1, 1990·Gynecologic Oncology·M BruzzoneR Rosso
Sep 1, 1989·Gynecologic Oncology·J DauplatR Plagne
Apr 15, 1989·Cancer·J MenczerH Brenner
Sep 21, 1988·Journal of the National Cancer Institute·M J PiccartG Atassi
Feb 1, 1980·Toxicology and Applied Pharmacology·C S Weil, S C Gad
Jan 1, 1981·Cancer·A B MillerA Winkler
Feb 15, 1993·Cancer·M MarkmanP Saigo
Citations
Aug 8, 2001·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·P F ConteC Cianci
May 14, 2009·Therapeutics and Clinical Risk Management·Maurie Markman
Aug 10, 2007·Expert Opinion on Investigational Drugs·Daniela Matei
Dec 6, 2000·Gynecologic Oncology·A GadducciA Riccardo Genazzani
May 14, 2005·Critical Reviews in Oncology/hematology·Angiolo GadducciAndrea Riccardo Genazzani
Jun 7, 2013·The Cochrane Database of Systematic Reviews·Aramide O LawalLiesl Grobler
Aug 5, 2000·Bone Marrow Transplantation·F BertucciD Maraninchi
May 24, 2005·Bone Marrow Transplantation·C BengalaUNKNOWN EBMT Solid Tumor Working Party
Dec 21, 2000·Current Oncology Reports·C S Chu, S C Rubin
Feb 6, 2008·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·A Gadducci, P F Conte
Aug 12, 2004·British Journal of Cancer·G D HallT J Perren
Nov 1, 2002·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Sundar SanthanamKen O'Byrne
Jan 9, 2019·Journal of Gastrointestinal Cancer·Keishla M GarcíaÁngel M Rodríguez
Sep 25, 2017·Oncotarget·Lili YangHaipeng Zhang
Feb 27, 1999·Current Opinion in Obstetrics & Gynecology·S MakhijaR R Barakat
Mar 17, 2012·Clinical Pharmacokinetics·Csilla Hasovits, Stephen Clarke
Nov 10, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Yumi TakemotoMasamichi Kojiro